{"filing":{"accession_number":"0001641489-26-000029","cik":"0001641489","ticker":"VTVT","company_name":"vTv Therapeutics Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"vtvt-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/vtvt-20260806.htm"},"events":[{"id":25925,"run_id":23539,"accession_number":"0001641489-26-000029","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"vTv Therapeutics issued a press release on August 6, 2026, announcing financial results for the fiscal period ended June 30, 2026, including condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $13.1 million, cash position of $86.6 million) and six-month results. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway through anticipated clinical trial data readout.","company_name":"vTv Therapeutics Inc.","ticker":"VTVT","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26866,"accession_number":"0001641489-26-000029","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"vTv Therapeutics issued a press release on August 6, 2026, announcing financial results for the fiscal period ended June 30, 2026, including condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $13.1 million, cash position of $86.6 million) and six-month results. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway through anticipated clinical trial data readout.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:18.377993+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26866,"accession_number":"0001641489-26-000029","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"vTv Therapeutics issued a press release on August 6, 2026, announcing financial results for the fiscal period ended June 30, 2026, including condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $13.1 million, cash position of $86.6 million) and six-month results. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway through anticipated clinical trial data readout.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:47:18.377993+00:00","company_name":"vTv Therapeutics Inc.","ticker":"VTVT","filing_date":"2026-08-06"}]}